Further, patient survival data also showed reduced progression free survival and poor prognosis of lung cancer patients carrying CAV-1 mutation, and the disease-free survival among those patients was 50 months as compared to more than 179 months for patients without CAV-1 genetic alteration (Fig 8). This evidence concerns the gene CAV1 and lung carcinoma.